Cannabinoids Effects on the Pain Modulation System
关键词
抽象
日期
| 最后验证: | 05/31/2018 |
| 首次提交: | 09/23/2015 |
| 提交的预估入学人数: | 09/23/2015 |
| 首次发布: | 09/24/2015 |
| 上次提交的更新: | 06/11/2018 |
| 最近更新发布: | 06/13/2018 |
| 实际学习开始日期: | 08/31/2015 |
| 预计主要完成日期: | 08/31/2019 |
| 预计完成日期: | 08/31/2019 |
状况或疾病
干预/治疗
Drug: Cannabis oil
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Active Comparator: Cannabis oil Cannabis oil, 20% THC 0.2 mg/kg | |
| Placebo Comparator: Placebo Oil |
资格标准
| 有资格学习的年龄 | 25 Years 至 25 Years |
| 有资格学习的性别 | Male |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: A. Men aged 25-65. B. Were not treated with formulation contains Cannabis C. Can sign an informed consent form. D. Patients have a medical history that supports severe neuropathic pain over Three months And do not respond to other painkillers or suffer from side effects resulting from the use them E. At least moderate pain (more than 40 on a scale of 0-100 visual analogue scale). F. Did not receive epidural injection or invasive treatment in The last month before the entry to study . G. Not drinking alcohol or consuming high concentrations of opioid and Benzodiazifinim over 24 Hours before the experiment (equivalent to 40 mg morphine). Exclusion Criteria: A. Patients that found with serious level of anxiety in Patient Health Questionnaire (PHQ-9) . (These patients will be recommended by a doctor appointment with a psychiatrist). B.Patients with psychiatric problems or a family history of psychiatric disorders. C.Patients with known cardiovascular problems D.Patients with neurological problems from a central source E.Patients taking blood pressure medication F.Patients who are unable to understand and follow the instruction of the study. G.Diffuse pain syndromes from uncertain origin (like fibromyalgia) H.Alcoholism or chronic use of drugs. I.Malignant |
结果
主要结果指标
1. evaluation of pain [1 months]
次要成果指标
1. Testing of the pain and pain-modulation system [1 months]
2. Functional brain correlates [1 month]
